StonvexLoading…
StonvexStonvexStonvexReal-time TradingView chart with full indicator set.
Last 7 days, powered by Finnhub. Tap Analyze to classify direction.
Loading latest news…
Pick the depth your tier unlocks. Logged-in Pro/Premium users automatically get the deeper report.
Free preview · 3 reports / hour · No sign-up required
Factor grades, AI Copilot, personalized ranking, and deeper event analysis.
Upgrade to Pro →Next report date, year-over-year trend, and recent quarter history.
5-factor analysis: Valuation, Growth, Profitability, Momentum, Financial Health.
Factor scoring needs Finnhub-supplied fundamentals — Finnhub returned no fundamental metrics for this ticker. Common for ETFs, foreign filers without US listing depth, recent IPOs, and thinly-traded OTC names.
6-factor scoring with sector-relative rank. Updated daily.
Share this analysis with other traders
Disclaimer: The content on this page is for informational and educational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any security. Past performance does not guarantee future results. Consult a licensed financial advisor before making any investment decisions.
Quarterly filings sourced directly from SEC EDGAR. Real-time earnings actuals are in the Earnings panel above.
| Date | Open | Close | Δ | Vol |
|---|---|---|---|---|
| 05-11 | $4.90 | $4.84 | -1.12% | 0.0M |
| 05-12 | $4.84 | $4.83 | -0.31% | 0.0M |
| 05-13 | $4.75 | $4.76 | +0.21% | 0.0M |
| 05-14 | $4.78 | $4.79 | +0.31% | 0.0M |
| 05-15 | $4.67 | $4.77 | +2.14% | 0.0M |
Documents are served directly from sec.gov / the issuer's website — Stonvex does not proxy or store filings.
| Metric | Annual 2022 2022-12-31 | Q3 2022 2022-09-30 | Q2 2022 2022-06-30 | Q1 2022 2022-03-31 |
|---|---|---|---|---|
Revenue | $3.11M | $3.11M | $3.11M | $3.11M |
Operating Income | $-28.64M | $-20.96M | $-13.17M | $-5.61M |
Net Income | $8.03M | $12.67M | $28.01M | $-7.70M |
EPS (Diluted) | $1.57 | $2.52 | $4.08 | $-1.55 |
Total Assets | $34.22M | $31.70M | $38.80M | $45.18M |
Total Liabilities | $16.24M | $15.93M | $15.75M | $51.07M |
Cash & Equivalents | $22.64M | $22.15M | $29.43M | $34.99M |
Free Cash Flow OCF − CapEx | $-21.05M | $-15.11M | $-8.21M | Not available |
Shares Outstanding | 6.47M | 5.09M | 5.09M | 5.01M |
Aptevo Therapeutics Inc is a clinical-stage research and development biotechnology company focused on developing novel immunotherapeutic candidates for the treatment of different forms of cancer. Its clinical candidates are; ALG.APV-527, which targets co-stimulatory receptors and tumor antigens, and CD3xCD123, which is being developed as a potential treatment of frontline acute myelogenous leukemia. The company's preclinical candidates, APVO711, CD3xCD123, APVO0442, and APVO603, are being developed using the ADAPTIR modular protein technology platform. The company's versatile and robust ADAPTIR and ADAPTIR-FLEX platforms are designed to generate monospecific, bispecific, and multi-specific antibody candidates that are capable of enhancing the human immune system against cancer cells.
These are published opinions from external sell-side analysts — not Stonvex recommendations. Ratings may change without notice, may conflict with each other, and may be wrong. Not investment advice.
Consensus aggregated from publicly disclosed sell-side analyst ratings. Stonvex is not a registered investment advisor and does not endorse any of the ratings shown. Past analyst ratings do not predict future price movements.